Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $22.35, for a total value of $111,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Audentes Therapeutics, Inc. (BOLD) opened at 24.35 on Tuesday. The company has a 50-day moving average of $20.22 and a 200 day moving average of $17.37. The company’s market cap is $676.54 million. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $24.50.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.10. On average, equities analysts forecast that Audentes Therapeutics, Inc. will post ($3.53) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/12/audentes-therapeutics-inc-bold-major-shareholder-orbimed-advisors-llc-sells-5000-shares.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Audentes Therapeutics by 278.5% during the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the period. Nationwide Fund Advisors increased its position in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the period. Citadel Advisors LLC purchased a new position in shares of Audentes Therapeutics during the first quarter valued at about $184,000. State of Wisconsin Investment Board purchased a new position in shares of Audentes Therapeutics during the second quarter valued at about $210,000. Finally, Rhumbline Advisers purchased a new position in shares of Audentes Therapeutics during the second quarter valued at about $252,000. Institutional investors own 77.01% of the company’s stock.

BOLD has been the subject of several research reports. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday, July 17th. Wedbush restated an “ourperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research note on Monday, May 15th. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 20th. Finally, Evercore ISI initiated coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $22.40.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Stock Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related stocks with our FREE daily email newsletter.